The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Perioperative chemotherapy with docetaxel, cisplatin, and capecitabine (DCX) in gastroesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
P. C. Thuss-Patience
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Roche; Sanofi
R. Hofheinz
Honoraria - Roche; Sanofi
D. Arnold
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Roche; Sanofi
A. Florschütz
No relevant relationships to disclose
S. Daum
No relevant relationships to disclose
A. Kretzschmar
No relevant relationships to disclose
L. Mantovani-Löffler
No relevant relationships to disclose
D. Bichev
No relevant relationships to disclose
B. Gahn
No relevant relationships to disclose
G. Schumacher
No relevant relationships to disclose
M. Kneba
No relevant relationships to disclose